Two longevity drugs at opposite ends of the risk-benefit spectrum
What this is
Head-to-head evidence table: Rapamycin (mTOR inhibitor) vs Metformin (AMPK activator) (compound).
Why it matters
Rapamycin and metformin are the two most-discussed longevity pharmaceuticals — both with ITP (Interventions Testing Program) lifespan extension data in mice and ongoing human aging trials. They operate on partially overlapping but mechanistically distinct pathways: rapamycin directly inhibits mTORC1 (the longevity program's master switch), while metformin activates AMPK, which in turn suppresses mTORC1 indirectly and improves glucose metabolism. Rapamycin has dramatically stronger preclinical longevity data; metformin has a 60-year human safety record and is the subject of the TAME trial.
What to do next
Use the verdict row to pick a primary compound, then open both deep-dives and /shop verification checklists.
Rapamycin and metformin are the two most-discussed longevity pharmaceuticals — both with ITP (Interventions Testing Program) lifespan extension data in mice and ongoing human aging trials. They operate on partially overlapping but mechanistically distinct pathways: rapamycin directly inhibits mTORC1 (the longevity program's master switch), while metformin activates AMPK, which in turn suppresses mTORC1 indirectly and improves glucose metabolism. Rapamycin has dramatically stronger preclinical longevity data; metformin has a 60-year human safety record and is the subject of the TAME trial.
ITP lifespan extension (mice)
Rapamycin is the most replicated ITP longevity result; metformin results are inconsistent across labs
Rapamycin (mTOR inhibitor)
Significant: 9–14% median lifespan increase, starting as late as 20 months old (equivalent to ~60 human years)
Metformin (AMPK activator)
Modest: ~5% lifespan increase; some ITP cohorts showed no effect
Primary mechanism
Rapamycin hits mTOR directly; metformin hits it indirectly via energy-sensing
Rapamycin (mTOR inhibitor)
Direct mTORC1 inhibition → autophagy, reduced protein synthesis, immune modulation
Metformin (AMPK activator)
AMPK activation → mTORC1 suppression, improved insulin sensitivity, Complex I inhibition
Human safety record
Metformin has vastly superior safety track record at therapeutic doses
Rapamycin (mTOR inhibitor)
30+ years post-transplant use at immunosuppressive doses; cyclic low-dose is under-studied
Metformin (AMPK activator)
60+ years clinical use; billions of patient-years; one of the best-characterized drugs in medicine
Human longevity RCT
Neither has completed a primary endpoint longevity RCT in healthy humans as of 2026
Rapamycin (mTOR inhibitor)
PEARL trial (rapamycin, enrolled 2022); no published longevity primary endpoints yet
Metformin (AMPK activator)
TAME trial (NCT03107884): n=3,000 registered, targets aging as a disease endpoint; results ~2027
OTC accessibility
Rapamycin (mTOR inhibitor)
Prescription only; off-label for longevity in the US; typically $30–80/month at low longevity dose
Metformin (AMPK activator)
Prescription in US (widely prescribed for T2D, often covered by insurance); generic ~$4/month
Immune effects
Rapamycin's immune effects are dose-dependent and bidirectional — requires monitoring
Rapamycin (mTOR inhibitor)
Immunosuppressive at high doses; cyclic low-dose (1–6 mg/week) may enhance immune function in older adults
Metformin (AMPK activator)
Immunomodulatory — reduces inflammaging markers; generally no clinically significant immunosuppression
Muscle preservation
Neither compound is ideal for athletes; both can blunt training adaptation
Rapamycin (mTOR inhibitor)
Controversial — high doses impair mTORC2/muscle; cyclic dosing may avoid this
Metformin (AMPK activator)
Slight reduction in VO2max at high aerobic training loads (Malin 2019); generally neutral to muscle
Physician oversight required
Rapamycin (mTOR inhibitor)
High — requires CBC, metabolic panel, lipid panel, wound-healing monitoring; prescription-only
Metformin (AMPK activator)
Moderate — prescription required; basic kidney function monitoring (eGFR); well understood by GPs
TNiC verdict
Metformin is the accessible, physician-prescribable longevity intervention with excellent safety data. Rapamycin has superior preclinical longevity efficacy but requires physician oversight, cyclic dosing, and immune monitoring. They are not mutually exclusive — some longevity clinicians combine them at low doses with careful monitoring.
Choose Rapamycin (mTOR inhibitor) when
Choose Metformin (AMPK activator) when